Currently out of the existing stock ratings of Gary Nachman, 178 are a BUY (67.17%), 85 are a HOLD (32.08%), 2 are a SELL (0.75%).

Gary Nachman

Work Performance Price Targets & Ratings Chart

Analyst Gary Nachman, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 45.85% that have a potential upside of 52.98% achieved within 354 days.

Gary Nachman’s has documented 524 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PHAT, Phathom Pharmaceuticals at 12-Dec-2025.

Wall Street Analyst Gary Nachman

Analyst best performing recommendations are on LCI (LANNETT COMPANY).
The best stock recommendation documented was for MNK (MALLINCKRODT PLC) at 9/5/2019. The price target of $3 was fulfilled within 5 days with a profit of $1.41 (88.68%) receiving and performance score of 177.36.

Average potential price target upside

of $149.7 (52.47%) on OPTN (OPTINOSE).
of $36.69 (28.95%) on ABBV (ABBVIE).
of $25.67 (65.76%) on IONS (IONIS PHARMACEUTICALS).

AMPH Amphastar P APTX Aptinyx AQST Aquestive Therapeutics BHC Bausch Health Companies ENDP Endo International PLC FLXN Flexion Therapeutics HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC LCI Lannett Company MNK Mallinckrodt plc MYL Viatris NEOS Neos Therapeutics OPTN OptiNose PCRX Pacira Pharmaceuticals SAGE Sage Therapeutic ABBV AbbVie PHAT Phathom Pharmaceuticals RIGL Rigel Pharmaceuticals PYPD PolyPid VTRS Viatris SRRK Scholar Rock Holding Corp TEVA Teva Pharma Industries Ltd ADR MORF Morphic ALNY Alnylam Pharmaceuticals ABCL Abcellera Biologics EVLO Evelo Biosciences SDGR Schrodinger SLGL Sol Gel Technologies Ltd AMGN Amgen IONS Ionis Pharmaceuticals TRVI Trevi Therapeutics VERU Veru

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score